[go: up one dir, main page]

GR1006552B - Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract - Google Patents

Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract

Info

Publication number
GR1006552B
GR1006552B GR20080100303A GR20080100303A GR1006552B GR 1006552 B GR1006552 B GR 1006552B GR 20080100303 A GR20080100303 A GR 20080100303A GR 20080100303 A GR20080100303 A GR 20080100303A GR 1006552 B GR1006552 B GR 1006552B
Authority
GR
Greece
Prior art keywords
tissues
rapamycin
stent
lymph
prostate
Prior art date
Application number
GR20080100303A
Other languages
Greek (el)
Inventor
Νικολαος Χρηστου Δημοφιλος
Original Assignee
Νικολαος Χρηστου Δημοφιλος
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Νικολαος Χρηστου Δημοφιλος filed Critical Νικολαος Χρηστου Δημοφιλος
Priority to GR20080100303A priority Critical patent/GR1006552B/en
Priority to PCT/GR2009/000027 priority patent/WO2009130518A1/en
Publication of GR1006552B publication Critical patent/GR1006552B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00Materials or methods for coatings medical devices
    • A61L2420/08Coatings comprising two or more layers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Innovative use of the marketed Cypher (Cordis Company) and Shiga-stx/stxA toxins utilised before application of the stent described herein. Problem to be solved: impeding of the growth of hyperplasic benign or malignant tissues (soft tissues en general) due to the rapamycin acting on said tissues as well as on lymph cells (lymph tissues). It is disclosed a stent exhibiting known mechanical properties as well as immunostimulation activity when enriched with toxin. Possibility for depiction ofthe targeted hooking and thereby depiction of the tumour dynamic environment and pharmaceutical activity (drug carrier) in lymph tissues in general due to rapamycin utilization. Methodological stressing on all rapamycin utilizations (used alone, connected, or as a coating medium)on urologicorgans (kidney, prostate, ureter, lymphadens, testicle etc) as well as in lymph tissues in general (liquid-compact tissues) administrated in liquid form orally or directly applied on the tumour, alone or connected as referred to the description.
GR20080100303A 2008-04-24 2008-04-24 Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract GR1006552B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GR20080100303A GR1006552B (en) 2008-04-24 2008-04-24 Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract
PCT/GR2009/000027 WO2009130518A1 (en) 2008-04-24 2009-04-23 Intraprostatic stent coil-bar-pin infusion /injection method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20080100303A GR1006552B (en) 2008-04-24 2008-04-24 Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract

Publications (1)

Publication Number Publication Date
GR1006552B true GR1006552B (en) 2009-10-02

Family

ID=40791267

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20080100303A GR1006552B (en) 2008-04-24 2008-04-24 Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract

Country Status (2)

Country Link
GR (1) GR1006552B (en)
WO (1) WO2009130518A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10834A (en) * 2001-09-17 2015-09-04 Psivida Inc
US20050255230A1 (en) * 2004-05-17 2005-11-17 Clerc Claude O Method of manufacturing a covered stent
US20060067977A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
WO2006099470A2 (en) * 2005-03-15 2006-09-21 Surmodics, Inc. Compliant polymeric coatings for insertable medical articles
US20070162110A1 (en) * 2006-01-06 2007-07-12 Vipul Bhupendra Dave Bioabsorbable drug delivery devices

Also Published As

Publication number Publication date
WO2009130518A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
TR201809231T4 (en) Combination therapy with hyaluronidase and a tumor-driven taxane.
CL2009001014A1 (en) Superfast acting insulin composition comprising insulin and a hyaluronan degrading enzyme; closed loop system comprising the composition; method of preparing the composition; use of composition.
MX2010006991A (en) Therapeutic cancer treatments.
MX347298B (en) In vivo polynucleotide delivery conjugates having enzyme sensitive linkages.
MX2015013244A (en) Dissolvable gel-forming film for delivery of active agents.
RS53466B (en) Use of amisulpride for treating post-operative nausea and vomiting
MX2011003557A (en) Interface layer wound dressing.
DE602007010807D1 (en) DEVICE FOR COMBINED TREATMENT
WO2009127882A3 (en) A mobile wireless device with an embedded media player
PH12014500213A1 (en) Poly (acrylate) polymers for in vivo nucleic acid delivery
NZ591719A (en) Balloon catheter medical device coated with therapeutic agent and povidone-iodine
WO2011103146A3 (en) A post foaming gel composition comprising an anti-irritation agent
BR112013006331A2 (en) fulvestrant compositions and methods of use
WO2007128973A3 (en) Interleukin 1-receptor antagonist composition to treat restenosis
ATE528013T1 (en) VACCINE COMPOSITIONS
WO2011088178A3 (en) Personal care composition comprising a hydrophobically modified cationic polysaccharide
DK2124640T3 (en) Glucose isomerase for use in the treatment of fructose intolerance
WO2014121224A3 (en) Biodegradable iron oxide nanoparticle gel
TN2011000250A1 (en) Prophylactic/therapeutic agent for cancer
GR1006552B (en) Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract
EP4233536A3 (en) Method for enhancing tumor growth
Hammond-Thelin Cutaneous reactions related to systemic immunomodulators and targeted therapeutics
BRPI0716992A2 (en) histone deacetylase inhibitors with combined activity on histone deacetylases class i and class iib in combination with proteasome inhibitors
HK1201773A1 (en) Liquid activation system
FR2969312B1 (en) PHOTOVOLTAIC MODULE

Legal Events

Date Code Title Description
PG Patent granted